State-of-the-Art Review: Hepatitis C

Vincent Lo Re(University of Pennsylvania), Jessie Torgersen(Center for Clinical Research (United States)), H. Nina Kim(University of Washington), Andrew Aronsohn(University of Chicago), Jennifer C. Price(University of California, San Francisco), Matty Zimmerman(Penn Presbyterian Medical Center), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Debika Bhattacharya, Stacey Trooskin
Clinical Infectious Diseases
April 23, 2025
10.1093/cid/ciaf334
Cited by 3

Related Papers

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
|Mycoses|2011|159
Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
|The Lancet HIV|2019|140
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
|UNC Libraries|2020|111